Added to YB: 2025-06-26
Pitch date: 2025-06-25
NKTR [neutral]
Nektar Therapeutics
+75.61%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$1.1B
Pitch Price
$31.15
Price Target
69.00 (+26%)
Dividend
N/A
EV/EBITDA
-7.95
P/E
-6.87
EV/Sales
15.99
Sector
Pharmaceuticals
Category
growth
Deep Dive: Nektar Therapeutics $NKTR
NKTR (deep dive): Strong Rezpeg Phase 2b data in atopic dermatitis meets primary endpoint with high significance, showing efficacy comparable to leading biologics. Safety profile is clean with rapid onset, potentially distinguishing from competitors. Potential market: $17B+ in AD, plus alopecia opportunity. Analyst targets up dramatically (Jefferies: $2→$69). Cash runway to Q4 2026, Rezpeg Phase 3 planned for 2026.
Read full article (52 min)